These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 12229863)

  • 1. Drug metabolites in safety testing.
    Baillie TA; Cayen MN; Fouda H; Gerson RJ; Green JD; Grossman SJ; Klunk LJ; LeBlanc B; Perkins DG; Shipley LA
    Toxicol Appl Pharmacol; 2002 Aug; 182(3):188-96. PubMed ID: 12229863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A regulatory perspective on issues and approaches in characterizing human metabolites.
    Davis-Bruno KL; Atrakchi A
    Chem Res Toxicol; 2006 Dec; 19(12):1561-3. PubMed ID: 17173368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing Product Confidence-Shifting Paradigms.
    Phillips M; Kashyap V; Cheung MS
    PDA J Pharm Sci Technol; 2015; 69(6):736-42. PubMed ID: 26659104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and establishment of specifications for biopharmaceuticals.
    Davis GC; Riggin RM
    Dev Biol Stand; 1997; 91():49-54. PubMed ID: 9413683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current regulatory and scientific considerations for approving biosimilars in Iran.
    Hadavand N; Valadkhani M; Zarbakhsh A
    Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's Bioresearch Monitoring Program.
    Kelsey FO
    Methods Find Exp Clin Pharmacol; 1982; 4(7):503-8. PubMed ID: 7169836
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of an FDA guidance document for clinical trials in SLE.
    Siegel JN
    Lupus; 1999; 8(8):581-5. PubMed ID: 10568893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the "Metabolites in Safety Testing" Regulatory Guidance.
    Schadt S; Bister B; Chowdhury SK; Funk C; Hop CECA; Humphreys WG; Igarashi F; James AD; Kagan M; Khojasteh SC; Nedderman ANR; Prakash C; Runge F; Scheible H; Spracklin DK; Swart P; Tse S; Yuan J; Obach RS
    Drug Metab Dispos; 2018 Jun; 46(6):865-878. PubMed ID: 29487142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards regulation of similar biotherapeutic products: Thailand's perspective.
    Thanaphollert P; Tungsanga K
    Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organ Tech Rep Ser; 2003; 917():i-viii, 1-125, back cover. PubMed ID: 15024913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.
    Piccotti JR; Lebrec HN; Evans E; Herzyk DJ; Hastings KL; Burns-Naas LA; Gourley IS; Wierda D; Kawabata TT
    J Immunotoxicol; 2009 Mar; 6(1):1-10. PubMed ID: 19519157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of metabolite safety testing from an industry perspective.
    Anderson S; Knadler MP; Luffer-Atlas D
    Bioanalysis; 2010 Jul; 2(7):1249-61. PubMed ID: 21083238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical investigators and the pharmaceutical industry.
    Bellin E
    N Engl J Med; 2000 Aug; 343(7):511. PubMed ID: 10950676
    [No Abstract]   [Full Text] [Related]  

  • 14. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 15. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-diagnostic codevelopment strategies: FDA and industry dialog at the 4th FDA/DIA/PhRMA/PWG/BIO Pharmacogenomics Workshop.
    Hinman L; Spear B; Tsuchihashi Z; Kelly J; Bross P; Goodsaid F; Kalush F
    Pharmacogenomics; 2009 Jan; 10(1):127-36. PubMed ID: 19102722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug efficacy--double-blind studies.
    Basmajian JV; Adler P; Ord RL
    J Rehabil; 1974; 40(5):26-30. PubMed ID: 4606453
    [No Abstract]   [Full Text] [Related]  

  • 19. Current opinion: safety evaluation of drug metabolites in development of pharmaceuticals.
    Naito S; Furuta S; Yoshida T; Kitada M; Fueki O; Unno T; Ohno Y; Onodera H; Kawamura N; Kurokawa M; Sagami F; Shinoda K; Nakazawa T; Yamazaki T
    J Toxicol Sci; 2007 Oct; 32(4):329-41. PubMed ID: 17965548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WHO Expert Committee on Specifications for Pharmaceutical Preparations.
    World Health Organization Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2003; 908():i-viii, 1-136, back cover. PubMed ID: 12768889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.